CASI Pharmaceuticals, Inc. CASI
Set alert
As of Mar 17, 9:30 AM ET
- YTD
- -82.29%
- 1 year
- -92.24%
- Open
- 0.15
- Prev close
- 0.1505
- Mkt cap
- 41.44M
- Vol
- 7.90K
- Avg vol
- 40.10K
- EPS
- -2.23
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.15
- High
- 0.1505
- Forward P/E
- -1.26
- Beta
- 0.65
- Short ratio
- 2.36
- Inst. own
- 26.01%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 4.82
- 200-d avg
- 4.74
- 1y target
- 6.00
Discussion (1)
Sign in to join the discussion
VICKY HANUKA CASI 3 years ago #1Royalty Pharma Announces Agreement to Purchase Up to $1.5 Billion of PTC Therapeutics' Royalty on Evrysdi
-- Royalty Pharma purchases a portion of royalties on Roche's Evrysdi for
$1.0 billion upfront
-- PTC Therapeutics has option to sell rest of royalty for up to $500
million; Royalty Pharma has option to buy half of rest of royalty for up
to $250 million
-- Transaction expected to enhance long-term Adjusted Cash Receipts growth
(non-GAAP)
-- Royalty Pharma to host conference call today, Thursday, October 19 at
9:00am EDT
NEW YORK, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today an agreement with PTC Therapeutics, Inc. to acquire additional royalties on Roche's Evrysdi for $1.0 billion upfront. The agreement includes options for PTC to sell up to all of its retained royalties on Evrysdi for up to $500 million or for Royalty Pharma to acquire half of such retained royalties for up to $250 million at a later date.